FASN inhibitors were tested alone and in combination with EGFR TKIs (gefitinib and osimertinib) in EGFRm NSCLC models resistant to EGFR TKIs (Gefitinib Resistant, GR). The gene discussed is FASN; the disease is non-small cell lung carcinoma.